CSI Market
Sign In | Register

G1 Therapeutics Inc (GTHX) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access GTHX Annual Cash Flow →
The cash flow figures below highlight longer-term patterns in how G1 Therapeutics Inc manages cash inflows and outflows over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2024)
6 Months 		(Mar 31 2024) (Dec 31 2023) (Sep 30 2023) (Jun 30 2023)
Operating Activities
Income-15.69
Depreciation & amortization0.24
Amortization of Other Assets0.13
Increase (Decrease) in Deferred Revenue-0.17
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-0.94
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation4.64
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Purchase Of License Agreement-
Non Cash Interest Expense0.49
Non Cash Equity Interest Net-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-0.62
Increase (Decrease) in Accounts Payable1.14
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-6.30
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets2.76
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.16
Discontinued operations0.00
Net Cash flow from Operating Activities-14.17
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities59.20
Payments to Acquire Marketable Securities-53.68
Real Estate Investments0.00
Payment For Investment In Restricted Cash Account-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities5.52
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-0.55
Long-term debt - borrowings-8.20
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.26
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Stock Options And Warrants Exercised-
Temporary Equity Accretion To Redemption Value Adjustment-
Capital Expenditures Incurred But Not Yet Paid-
Conversion Of Preferred Stock And Preferred Warrants To Common Stock And Common Warrants-
Deferred Offering Costs Reclassified To Additional Paid In Capital-
Costs For Public Offering In Accounts Payable-
Proceeds From Loan Agreement-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-8.49
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-14.17
Total Cash Flow-17.14
4 historic quarters locked

Sign in to unlock the full G1 Therapeutics Inc cash flow history.

Sign In Create Free Account

About G1 Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001628280-24-036149

Figures are derived from filed reports and may be restated. Historical data is subject to revision.